Acticor Biotech SAS
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
Acticor Biotech SAS - Asset Resilience Ratio
Acticor Biotech SAS (ALACT) has an Asset Resilience Ratio of 0.06% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2020)
This chart shows how Acticor Biotech SAS's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Acticor Biotech SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €6.06K | 0.06% |
| Total Liquid Assets | €6.06K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Acticor Biotech SAS maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Acticor Biotech SAS Industry Peers by Asset Resilience Ratio
Compare Acticor Biotech SAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Acticor Biotech SAS (2007–2020)
The table below shows the annual Asset Resilience Ratio data for Acticor Biotech SAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.06% | €6.06K | €11.02 Million | +0.05pp |
| 2019-12-31 | 0.01% | €1.20K | €15.40 Million | -0.12pp |
| 2018-12-31 | 0.13% | €15.12K | €11.41 Million | -18.70pp |
| 2017-12-31 | 18.83% | €391.38K | €2.08 Million | +17.41pp |
| 2016-12-31 | 1.42% | €406.82K | €28.59 Million | -5.44pp |
| 2015-12-31 | 6.86% | €2.06 Million | €30.07 Million | -12.20pp |
| 2014-12-31 | 19.05% | €5.99 Million | €31.41 Million | +6.08pp |
| 2013-12-31 | 12.98% | €4.27 Million | €32.90 Million | -11.03pp |
| 2012-12-31 | 24.00% | €6.85 Million | €28.55 Million | -16.84pp |
| 2011-12-31 | 40.84% | €8.81 Million | €21.58 Million | +11.56pp |
| 2010-12-31 | 29.29% | €2.08 Million | €7.09 Million | -25.11pp |
| 2008-12-31 | 54.39% | €1.92 Million | €3.53 Million | +32.40pp |
| 2007-12-31 | 21.99% | €241.00K | €1.10 Million | -- |